MX2008015649A - Sustratos e inhibidores de enzima de escision de antiplasma y metodos de uso. - Google Patents

Sustratos e inhibidores de enzima de escision de antiplasma y metodos de uso.

Info

Publication number
MX2008015649A
MX2008015649A MX2008015649A MX2008015649A MX2008015649A MX 2008015649 A MX2008015649 A MX 2008015649A MX 2008015649 A MX2008015649 A MX 2008015649A MX 2008015649 A MX2008015649 A MX 2008015649A MX 2008015649 A MX2008015649 A MX 2008015649A
Authority
MX
Mexico
Prior art keywords
antiplasmin
plasma
asn
met
level
Prior art date
Application number
MX2008015649A
Other languages
English (en)
Spanish (es)
Inventor
Patrick A Mckee
Kyung N Lee
Kenneth W Jackson
Victoria J Christiansen
Original Assignee
Patrick A Mckee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patrick A Mckee filed Critical Patrick A Mckee
Publication of MX2008015649A publication Critical patent/MX2008015649A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
MX2008015649A 2006-06-07 2007-06-06 Sustratos e inhibidores de enzima de escision de antiplasma y metodos de uso. MX2008015649A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81156806P 2006-06-07 2006-06-07
US83636506P 2006-08-08 2006-08-08
PCT/US2007/013480 WO2007146104A2 (fr) 2006-06-07 2007-06-06 Substrats et inhibiteurs de l'enzyme de clivage de l'antiplasmine et procédés d'utilisation

Publications (1)

Publication Number Publication Date
MX2008015649A true MX2008015649A (es) 2009-03-25

Family

ID=38832396

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008015649A MX2008015649A (es) 2006-06-07 2007-06-06 Sustratos e inhibidores de enzima de escision de antiplasma y metodos de uso.

Country Status (6)

Country Link
EP (1) EP2038653A4 (fr)
JP (1) JP2009539853A (fr)
AU (1) AU2007258495A1 (fr)
CA (1) CA2658331A1 (fr)
MX (1) MX2008015649A (fr)
WO (1) WO2007146104A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933201B2 (en) 2006-06-07 2015-01-13 The Board Of Regents Of The University Of Oklahoma Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
WO2018111989A1 (fr) 2016-12-14 2018-06-21 Purdue Research Foundation Imagerie et thérapie ciblées par une protéine d'activation des fibroblastes (fap)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309774B2 (en) * 2003-02-07 2007-12-18 The Board Of Regents Of The University Of Oklahoma Antiplasmin cleaving enzyme

Also Published As

Publication number Publication date
CA2658331A1 (fr) 2007-12-21
AU2007258495A1 (en) 2007-12-21
WO2007146104A2 (fr) 2007-12-21
EP2038653A4 (fr) 2010-04-21
JP2009539853A (ja) 2009-11-19
EP2038653A2 (fr) 2009-03-25
WO2007146104A3 (fr) 2008-10-16

Similar Documents

Publication Publication Date Title
EP0912601B2 (fr) Suppression de reponse immunitaire par inhibition de cathepsine s
JPH05500801A (ja) アルツハイマーアミロイドポリペプチドを使用した薬学的組成物および処置方法
AU2843900A (en) Proteins that bind angiogenesis-inhibiting proteins, compositions and methods of use thereof
JP2010530238A5 (fr)
US20080118933A1 (en) Methods of screening for inhibitors of antiplasmin cleaving enzyme
AU2009246603B8 (en) von Willebrand Factor (VWF) inhibitors for treatment or prevention of infarction
WO1999043809A2 (fr) Recepteur 4 active par la protease et ses utilisations
EP4079322A1 (fr) Compositions pour le traitement de troubles de la calcification ectopique et procédés les utilisant
US5846755A (en) Method for determining the therapeutic activity of metalloproteinase inhibitor compounds
US7897334B2 (en) Skin treatment
US7189699B2 (en) Peptides for the treatment of Alzheimer's disease and other β-amyloid protein fibrillogenesis disorders
CZ334095A3 (en) Compounds containing chains of amino acids, their use and pharmaceutical compositions containing thereof
MX2008015649A (es) Sustratos e inhibidores de enzima de escision de antiplasma y metodos de uso.
US20180200330A1 (en) Compositions and Methods for the Treatment of Diseases Related to the Renin-Angiotensin-System
US20080057491A1 (en) Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use
US6207419B1 (en) Thrombin inhibitory agents and methods of using same
Riillo et al. c. 376A> G,(p. Ser126Gly) Alpha-Galactosidase A mutation induces ER stress, unfolded protein response and reduced enzyme trafficking to lysosome: Possible relevance in the pathogenesis of late-onset forms of Fabry Disease
US9670250B2 (en) Alpha-helical peptidomimetic inhibitors and methods using same
UA75867C2 (en) A method of determining the presence of catalytic factor viii allo-antibodies capable of degrading factor viii in a mammal, amino acid sequence inhibiting any site in factor viii molecule being sensible to cleavage by allo-antibodies in factor viii (variants), use of inhibitor of cleavage of factor viii to neutralize a catalytic activity of allo-antibodies to factor viii and pharmaceutical composition containing allo-antibodies being capable of degrading factor viii
US20230002510A1 (en) Cela-1 inhibition for treatment of lung disease
JP2006512308A (ja) 糖尿病関連及び／又は動脈低治癒性創傷の治療及び／又は予防のための、α−１−アンチキモトリプシン（ａｎｔｉｃｈｙｍｏｔｒｙｐｓｉｎ）ポリペプチドまたはそれをコードしている核酸の、α−１−アンチトリプシン（ａｎｔｉｔｒｙｐｓｉｎ）ポリペプチドまたはそれをコードしている核酸と組み合わせた使用
CN101512338A (zh) 抗纤维蛋白溶酶切割酶的底物和抑制剂及其应用方法
Héry-Huynh et al. Induction and regulation of murine emphysema by elastin peptides 2
CN114981661A (zh) 用于诊断与嗜中性粒细胞胞外陷阱相关的纤溶功能不全的方法
EP2893925A1 (fr) Compositions et procédés pour le traitement de maladies liées au système rénine-angiotensine

Legal Events

Date Code Title Description
FA Abandonment or withdrawal